RELZEPTIS Trademark

Trademark Overview

On Tuesday, August 30, 2016, a trademark application was filed for RELZEPTIS with the United States Patent and Trademark Office. The USPTO has given the RELZEPTIS trademark a serial number of 79194618. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, January 12, 2024. This trademark is owned by CROSSJECT. The RELZEPTIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of polyarthritis and autoimmune diseases
relzeptis

General Information

Serial Number79194618
Word MarkRELZEPTIS
Filing DateTuesday, August 30, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, January 12, 2024
Registration Number5229996
Registration DateTuesday, June 27, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2017

Trademark Statements

Goods and ServicesPharmaceutical products, namely, pharmaceutical preparations for the treatment of polyarthritis and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, January 12, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCROSSJECT
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressFR
Party NameCROSSJECT
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressFR
Party NameCROSSJECT
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressFR

Trademark Events

Event DateEvent Description
Friday, December 9, 2016ASSIGNED TO EXAMINER
Thursday, October 27, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, October 31, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 4, 2016APPLICATION FILING RECEIPT MAILED
Thursday, December 15, 2016NON-FINAL ACTION WRITTEN
Friday, December 16, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, December 19, 2016REFUSAL PROCESSED BY MPU
Monday, December 19, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, March 6, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, January 6, 2017REFUSAL PROCESSED BY IB
Monday, January 23, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 7, 2017ASSIGNED TO LIE
Wednesday, February 15, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 15, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 1, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2017PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 27, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, September 27, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, September 28, 2017FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, March 22, 2017NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 22, 2017NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Saturday, April 8, 2017NOTIFICATION PROCESSED BY IB
Thursday, September 28, 2017FINAL DISPOSITION PROCESSED
Monday, June 27, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, January 12, 2024CANCELLED SECTION 71
Friday, September 13, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Saturday, September 14, 2024TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, September 14, 2024INVALIDATION PROCESSED
Saturday, October 28, 2017FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

relzeptis pharmaceutical autoimmune diseases polyarthritis preparations products namely treatment